GlassScriptPhysician profile
Noah Matthew Camp
NPI 1477060879
$2,095.28
in general payments reported to CMS, 2019-2025
29 companies · $52.25 in 2025
The $52.25 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $555 · 2022: $901 · 2023: $587 · 2025: $52.25.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $639.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $638.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $288.17 | 2021-2023 | |
| Lilly USA, LLC | $267.31 | 2021-2023 | Mounjaro, Jardiance, Emgality |
| Astrazeneca Pharmaceuticals LP | $244.97 | 2021-2023 | Breztri, Farxiga |
| Novo Nordisk INC | $232.04 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $126.50 | 2021-2023 | Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $119.59 | 2021-2023 | Verquvo, Steglatro, Belsomra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $85.52 | 2021-2022 | |
| Boston Scientific Corporation | $76.35 | 2022 | |
| Amgen INC. | $63.49 | 2021-2025 | Repatha, Otezla |
| Currax Pharmaceuticals LLC | $48.59 | 2021-2022 | |
| Pfizer INC. | $48.46 | 2021-2023 | |
| Biohaven Pharmaceuticals, INC. | $48.14 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $46.87 | 2022 | |
| Medtronic, INC. | $42.23 | 2023 | Intellis Adaptivestim |
| Teva Pharmaceuticals USA, INC. | $41.14 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $40.12 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.10 | 2021-2022 | |
| Exact Sciences Corporation | $35.07 | 2023 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $27.41 | 2022 | |
| Amarin Pharma, INC. | $24.38 | 2021 | |
| Si-Bone, INC. | $22.86 | 2022 | |
| Grifols USA, LLC | $22.58 | 2021 | |
| Bioventus LLC | $18.94 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $15.73 | 2022 | |
| Novartis Pharmaceuticals Corporation | $15.65 | 2023 | |
| Astellas Pharma US INC | $15.11 | 2023 | Myrbetriq |
| Ironwood Pharmaceuticals, INC | $14.29 | 2022 | |
| Paratek Pharmaceuticals, INC. | $12.38 | 2022 | |
| Janssen Pharmaceuticals, INC | $12.29 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Noah Camp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.